Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Stril (Dorval, QC, Canada). Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study.. 3542

Member's Comments

No comment yet.

Related content which might interest you: Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Impact of subcutaneous allergoid AIT on patients with allergic rhinitis and/or asthma: A retrospective real-life, long-term cohort analysis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 The eXpeRience registry: Monitoring the ‘real-world‘ effectiveness of omalizumab in allergic asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011 Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007 Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study Source: International Congress 2017 – Asthma management Year: 2017 Real-world effectiveness of omalizumab in allergic asthma patients with low or high blood eosinophils: A retrospective claims analysis study Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting Source: International Congress 2017 – Asthma management Year: 2017 Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Cost effectiveness of omalizumab in Swedish asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 4 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 A population-based clinical study of allergic and non-allergic asthma Source: Annual Congress 2008 - Markers and triggers of asthma Year: 2008 A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008